Showing results (1-10 of 200) with videos related to
Sort By:
Pageof 20
Current Diabetes Reports|October 6, 2004
Women, type 2 diabetes, and fracture riskAnn V Schwartz, Deborah E SellmeyerExpert Opinion on Drug Safety|January 4, 2008
Effect of thiazolidinediones on skeletal health in women with Type 2 diabetesAnn V Schwartz, Deborah E SellmeyerCurrent Osteoporosis Reports|October 11, 2007
Diabetes, fracture, and bone fragilityAnn V Schwartz, Deborah E SellmeyerDiabetes Care|June 29, 2004
Effect of alendronate on bone mineral density and biochemical markers of bone turnover in type 2 diabetic women: the fracture intervention trialTheresa H M Keegan, Ann V Schwartz, Douglas C Bauer, et al.Diabetes|June 23, 2016
Skeletal Metabolism, Fracture Risk, and Fracture Outcomes in Type 1 and Type 2 DiabetesDeborah E Sellmeyer, Roberto Civitelli, Lorenz C Hofbauer, et al.JAMA|October 7, 2010
Atypical fractures as a potential complication of long-term bisphosphonate therapyDeborah E SellmeyerCurrent Osteoporosis Reports|January 9, 2021
Nutritional Supplements and Skeletal HealthLaila S Tabatabai, Deborah E SellmeyerJournal of Clinical Lipidology|April 11, 2017
The effect of dietary protein source on serum lipids: Secondary data analysis from a randomized clinical trialAnda R Gonciulea, Deborah E SellmeyerThe Journal of Clinical Endocrinology and Metabolism|May 8, 2002
Potassium citrate prevents increased urine calcium excretion and bone resorption induced by a high sodium chloride dietDeborah E Sellmeyer, Monique Schloetter, Anthony SebastianThe Journal of Clinical Endocrinology and Metabolism|October 14, 2011
Change in undercarboxylated osteocalcin is associated with changes in body weight, fat mass, and adiponectin: parathyroid hormone (1-84) or alendronate therapy in postmenopausal women with osteoporosis (the PaTH study)Anne L Schafer, Deborah E Sellmeyer, Ann V Schwartz, et al.Pageof 20